| | Family Health | Women's Health
DVT Risk Factors Across Demographics: Sex, Age, Race, and Special Populations
Demographic and Population-Specific Risk Factors for DVT
While DVT can affect anyone, incidence and risk factor profiles vary significantly across demographic groups. Understanding these differences aids in targeted screening, prevention, and equitable care.
Sex and Gender Differences
- Women have higher overall VTE incidence during reproductive years due to estrogen exposure (combined oral contraceptives, pregnancy, hormone therapy).
- Men have higher incidence after age 50, possibly due to higher rates of comorbid cardiovascular disease, cancer, and surgery.
- Pregnancy/postpartum: 5–10× increased risk; highest in first 6 weeks postpartum.
- Oral contraceptives: Estrogen-containing formulations increase risk 3–5×; higher with newer progestins (drospirenone, desogestrel).
- Hormone therapy: Oral estrogen increases risk; transdermal appears safer.
Age
- Incidence rises exponentially with age: <1/100,000/year in children → >500/100,000/year in >80-year-olds.
- Age >60 is an independent risk factor; >75 confers highest absolute risk.
- Age-related factors: reduced mobility, comorbidities, polypharmacy, venous wall changes.
Race and Ethnicity
- Black/African American individuals: Highest VTE incidence in U.S. (1.5–2× White rates). Higher rates of provoked and unprovoked VTE, earlier onset, more PE presentation, and higher case-fatality.
- Hispanic/Latino individuals: Intermediate rates; some studies show higher risk than Whites but lower than Blacks.
- White individuals: Reference population in most studies.
- Asian/Pacific Islander individuals: Historically lower reported rates, but increasing with Westernization; may have different thrombophilia profiles (e.g., lower Factor V Leiden, higher protein S deficiency in some groups).
- Contributing factors: Genetic (thrombophilia prevalence), socioeconomic (access to care, obesity, comorbidities), healthcare bias, and environmental factors all play roles.
Other Population-Specific Considerations
- Cancer patients: 4–7× higher risk; varies by cancer type (pancreas, brain, lung, stomach highest). Chemotherapy, surgery, central lines add risk.
- Surgical patients: Orthopedic (hip/knee replacement, fracture) highest risk without prophylaxis (40–60% DVT). Major abdominal/pelvic surgery also high risk.
- Hospitalized medical patients: Acutely ill (heart failure, respiratory failure, stroke, infection) have 10–15% DVT risk without prophylaxis.
- Pediatric: Rare but increasing; associated with central lines, malignancy, congenital heart disease, trauma, obesity.
- Transgender individuals on gender-affirming hormone therapy: Estrogen therapy confers VTE risk similar to combined OCs; risk assessment and counseling essential.
Implications for Clinical Practice
- Risk assessment tools (Caprini, Padua, IMPROVE) should incorporate demographic variables.
- Prophylaxis guidelines must account for population-specific baseline risks.
- Cultural competency in counseling about hormonal therapy, pregnancy, and lifestyle modification.
- Address disparities in VTE outcomes through equitable access to prophylaxis, diagnosis, and treatment.
DVT risk is not uniform—precision prevention requires understanding how demographics, biology, and social determinants intersect.
Women's Health - Related Articles
- Menopause Tests: Understanding Diagnostic Options & Hormone Levels
- Understanding Recurring Yeast Infections: Causes, Symptoms & Treatment
- Understanding Your Menstrual Cycle: A Comprehensive Guide
- Boost Natural Fertility: Simple Steps to Conceive
- Weight Loss After Menopause: A Guide for Women
- Delivery Room: Roles, Responsibilities & What to Expect
- Understanding Fibroids: Early Symptoms and What to Expect
